PURPOSE:Erlotinib is the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) which has demonstrated a survival benefit in non-small-cell lung cancer (NSCLC) patients. An open label phase II study was conducted in Taiwanese patients with NSCLC to evaluate its efficacy. METHODS:Patients with proven stage IIIB/IV NSCLC who had received at least one line of standard chemotherapy or radiotherapy were enrolled into this study. All patients were given oral erlotinib, 150mg/day till disease progression. RESULTS:From May 2005 to July 2006, 300 patients were entered from 14 hospitals in Taiwan. This analysis was based on 299 patients who received at least one dose of erlotinib. The best response rates were a 29% partial response and 44% stable disease in 273 patients who had response data available. Non-smoking (p=0.033), adenocarcinoma/BAC (p=0.0027), female (p=0.0013), aged less than 65 years (p=0.0115), stage IV (p=0.0492), patients with skin rash (p=0.0216), and a higher grade of skin rash (p=0.003) were significantly correlated with response to treatment. Skin rash was a common adverse event (any grade: 84%, Gr 3-4: 16%). The median time to disease progression was 5.6 months. Cox regression model for progression free survival showed patients most at risk of early progression were males of low performance status having squamous cell carcinoma. CONCLUSIONS:This was the largest multicenter prospective clinical study of NSCLC in Taiwan. The results demonstrated the excellent response rates, time-to-progression and overall survival of erlotinib in a large population of Taiwanese NSCLC patients who had been previously treated with chemotherapy or radiotherapy.

译文

目的:厄洛替尼是第一种表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),已证明在非小细胞肺癌(NSCLC)患者中具有生存获益。在台湾的NSCLC患者中进行了一项开放标签的II期研究,以评估其疗效。
方法:IIIB / IV期NSCLC阶段已被证实接受过至少一线标准化疗或放疗的患者被纳入本研究。所有患者均口服厄洛替尼,剂量为150mg /天,直至疾病进展。
结果:从2005年5月到2006年7月,来自台湾14所医院的300名患者进入了研究。该分析基于299名接受至少一剂厄洛替尼的患者。最好的缓解率是在有可用响应数据的273例患者中,部分缓解率为29%,疾病稳定率为44%。非吸烟(p = 0.033),腺癌/ BAC(p = 0.0027),女性(p = 0.0013),年龄小于65岁(p = 0.0115),IV期(p = 0.0492),皮疹患者(p = 0.0216),较高等级的皮疹(p = 0.003)与治疗反应显着相关。皮疹是常见的不良事件(任何等级:84%,Gr 3-4:16%)。疾病进展的中位时间为5.6个月。无进展生存期的Cox回归模型显示,处于早期进展风险最大的患者是表现为鳞状细胞癌的低性能男性。
结论:这是台湾地区最大的非小细胞肺癌多中心前瞻性临床研究。结果表明,在先前接受过化学疗法或放射疗法治疗的大量台湾NSCLC患者中,厄洛替尼具有出色的缓解率,进展时间和总体生存率。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录